An interventional study of Dorzagliatin and Linagliptin in Type 2 Diabetes Mellitus (T2DM), Chronic Renal Insufficiency and Chronic Kidney Disease (Stages 3b-5), sponsored by Sun Yat-sen University. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-08-26.
Sponsored by Sun Yat-sen University · Not applicable, Interventional, and Treatment
This study aims to evaluate whether dorzagliatin can improve glycemic homeostasis in patients with type 2 diabetes mellitus (T2DM) complicated by chronic renal insufficiency, and to compare the efficacy of dorzagliatin with linagliptin in improving glycemic control in patients with T2DM and moderate to severe chronic renal insufficiency (estimated glomerular filtration rate [eGFR] \<45 mL/min/1.73 m²).
This is a prospective, randomized, active-controlled, multicenter clinical study planned to enroll 206 eligible patients. After successful screening, patients will enter a 2-week run-in period consisting of diet and exercise control together with continuous glucose monitoring (CGM). Eligible patients will then be randomized to receive dorzagliatin 75 mg twice daily (BID) or linagliptin 5 mg once daily (QD) on top of background antihyperglycemic therapy. Basal insulin therapy will be standardized to insulin glargine U300 after treatment initiation. The treatment period will last 14 weeks, followed by a 1-week safety follow-up period.
This is a prospective, randomized, active-controlled, multicenter clinical study designed to enroll 206 eligible patients with T2DM complicated by moderate to severe chronic renal insufficiency.
Patients who pass screening will first enter a 2-week run-in period involving diet and exercise control and continuous glucose monitoring (CGM). Laboratory assessments and other relevant evaluations will be performed within 3 days prior to randomization.
At the randomization visit, eligibility will be reconfirmed according to the inclusion and exclusion criteria. Qualified patients will then be randomly assigned through a random number system to receive either dorzagliatin tablets 75 mg BID or linagliptin tablets 5 mg QD.
Both groups will receive study treatment on the basis of background antihyperglycemic therapy. Background antihyperglycemic therapy is defined as a stable glucose-lowering regimen used for at least 4 weeks prior to enrollment, consisting of basal insulin injection (excluding insulin-incretin combination preparations) and 0 to 2 oral antidiabetic drugs. Oral antidiabetic drugs are restricted to metformin, sodium-glucose cotransporter-2 (SGLT2) inhibitors, alpha-glucosidase inhibitors (AGIs), meglitinides, and thiazolidinediones (TZDs). After treatment initiation, basal insulin will be standardized to insulin glargine U300 in all patients.
The treatment duration is 14 weeks. At the end of treatment, investigational medication will be discontinued, followed by a 1-week safety follow-up period.
Exclusion Criteria:
Dorzagliatin tablets, 75 mg BID
Drug: Dorzagliatin
Linagliptin tablets, 5 mg QD
Drug: Linagliptin
insulin glargine U300 with 0-2 OAD
insulin glargine U300 with 0-2 OAD
Change in Time in Range (TIR, 3.9-10.0 mmol/L) from baseline to Week 14
To compare the change in TIR (3.9-10.0 mmol/L) from baseline to Week 14 between the dorzagliatin 75 mg BID group and the linagliptin 5 mg QD group in patients with T2DM complicated by moderate to severe chronic renal insufficiency.
Time frame: Baseline to Week 14
Change in HbA1c from baseline to Week 14
Time frame: Baseline to Week 14
Plan to share: No
No publications or documents are linked to this record.
This study is not yet recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Sun Yat-sen University